Placental tissue component compositions for treatment of skin defects and methods using same

Patent metadata

Field	Value
Publication number	US-2021093675-A1
Application number	US-202017106916-A
Country	US
Kind code	A1
Filing date	Nov 30, 2020
Priority date	May 18, 2018
Publication date	Apr 1, 2021
Grant date	—

Abstract

The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe, which may be for use in treating such defects.

First claim

What is claimed is:

1 . A method of treating a defect in a patient by injecting a composition comprising placental tissue components at the site of the defect.

2 . The method of claim 1 , wherein the placental tissue components are particles, said particles comprising placental disc and at least one of amniotic membrane, chorionic membrane, and umbilical cord.

3 . The method of claim 2 , wherein the particles comprise placental disc and amniotic membrane.

4 . The method of claim 2 , wherein the particles comprise placental disc and chorionic membrane.

5 . The method of claim 2 , wherein the particles comprise placental disc, amniotic membrane, and chorionic membrane.

6 . The method of claim 2 , wherein the particles comprise placental disc and umbilical cord.

7 . The method of claim 2 , wherein the particles comprise placental disc, amniotic membrane, chorionic membrane, and umbilical cord.

8 . The method of claim 2 , wherein the particles are rehydrated.

9 . The method of claim 2 , wherein the placental tissue components are or were previously dehydrated by lyophilization.

10 . The method of claim 2 , wherein the particles are micronized.

11 . The method of claim 9 , wherein the particles are 50-150 μm.

12 . The method of claim 10 , wherein the particles are 70-150 μm.

13 . The method of any one of claims 1 - 11 , wherein the defect is selected from the group consisting of scars and wrinkles.

14 . The method of any one of claims 1 - 7 , wherein the placental tissue components comprise about 1-20% dehydrated amniotic membrane and/or chorionic membrane particles if present, about 1-30% dehydrated umbilical cord particles if present, and about 50-98% dehydrated placental disc particles, by weight.

15 . The method of any one of claims 1 - 7 , wherein the placental tissue components comprise about 11-30% non-placental disc components.

16 . The method of any one of claims 1 - 15 , wherein the composition is injected by a method selected from the group consisting of subdermal, intradermal, and dermal.

17 . The method of any one of claims 1 - 16 , wherein the method is not repeated at the site of the treated defect until at least six months after the prior injection.

18 . A placental tissue composition maintained within the barrel of a syringe.

19 . The composition of claim 18 , said placental tissue composition comprising particles of placental disc and at least one of amniotic membrane, chorionic membrane, and umbilical cord.

20 . The composition of claim 19 , wherein the particles comprise placental disc and amniotic membrane.

21 . The composition of claim 19 , wherein the particles comprise placental disc and chorionic membrane.

22 . The composition of claim 19 , wherein the particles comprise placental disc, amniotic membrane, and chorionic membrane.

23 . The composition of claim 19 , wherein the particles comprise placental disc and umbilical cord.

24 . The composition of claim 19 , wherein the particles comprise placental disc, amniotic membrane, chorionic membrane, and umbilical cord.

25 . The composition of claim 19 , wherein the particles are rehydrated.

26 . The composition of claim 19 , wherein the placental tissue components are or were previously dehydrated by lyophilization.

27 . The composition of claim 19 , wherein said particles are micronized.

28 . The composition of claim 27 , wherein said micronized dehydrated particles are 50-150 μm.

29 . The composition of claim 28 , wherein said micronized dehydrated particles are 70-150 μm.

30 . The composition of any one of claims 17 - 29 , wherein the placental tissue components comprise about 1-20% dehydrated amniotic membrane and/or chorionic membrane particles if present, about 1-30% dehydrated umbilical cord particles if present, and about 50-98% dehydrated placental disc particles, by weight.

31 . The composition of any one of claims 17 - 29 , wherein the placental tissue components comprise about 11-30% non-placental disc components

32 . The composition of any one of claims 17 - 31 , for use in treating a scar or a wrinkle.

Assignees

• Mimedx Group Inc

Inventors

• Levaughn Rick
• Arjunon Sivakkumar
• Taylor Olivia

Classifications

• A61Q19/08

  Anti-ageing preparations · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K8/982

  Reproductive organs; Embryos, Eggs · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K35/51

  Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title